Jun Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jun Chen has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Kaixin Zhang
Department of Vascular Surgery, Suqian Hospital Affiliated to Xuzhou Medical University, (Nanjing Drum Tower Hospital Group Suqian Hospital), Suqian 223800, Jiangsu, China.
1 shared publication Shuo Wang
Department of Vascular Surgery, Suqian Hospital Affiliated to Xuzhou Medical University, (Nanjing Drum Tower Hospital Group Suqian Hospital), Suqian 223800, Jiangsu, China.
1 shared publication- Yi Yang
Department of Vascular Surgery, Suqian Hospital Affiliated to Xuzhou Medical University, (Nanjing Drum Tower Hospital Group Suqian Hospital), Suqian 223800, Jiangsu, China.
1 shared publication
Latest Publications
- Open Access
- 30 September 2023
- Published by CMB Association in Cellular and Molecular Biology
- Vol. 69 (9) , 183-188
Crocin improves lower extremity deep venous thrombosis by regulating the PIM1/FOXO3a axis
Lower extremity deep venous thrombosis (LEDVT) has a high incidence and mortality. Crocin has the potential to ameliorate thrombosis. The study aimed to clarify whether crocin affects LEDVT. Human umbilical vein endothelial cells (HUVECs) were exposed to thrombin and crocin (0, 5, 10, 20, 40, and 80 μM). Cell viability was assessed by MTT assay. Cellular behaviors were assessed using flow cytometry, TUNEL assay, and tube formation assay. The binding relationship between crocin and PIM1 was analyzed by molecular docking. The underlying mechanism of PIM1 was determined by reverse transcription-quantitative PCR, dual-luciferase reporter assay, and RIP. We found that crocin (5, 10, 20, and 40 μM) promoted thrombin-treated HUVEC viability in a dose-dependent manner. Crocin inhibited apoptosis and promoted the angiogenesis of HUVECs induced by thrombin. PIM1 was a target of crocin and was upregulated in patients with LEDVT and thrombin-treated cells. Foxo3a could interact with PIM1 and positively related to PIM1 expression. Moreover, the knockdown of PIM1 suppressed apoptosis and promoted angiogenesis in thrombin-HUVECs treated with crocin, while overexpression of Foxo3a reversed the effects. In conclusion, crocin inhibited apoptosis and promoted the angiogenesis of HUVECs induced by thrombin via the PIM1/Foxo3a axis, suggesting that crocin may be effective for LEDVT therapy.
- 30 September 2023
- Published by CMB Association in Cellular and Molecular Biology
- Vol. 69 (9) , 183-188
Open AccessCrocin improves lower extremity deep venous thrombosis by regulating the PIM1/FOXO3a axis
Lower extremity deep venous thrombosis (LEDVT) has a high incidence and mortality. Crocin has the potential to ameliorate thrombosis. The study aimed to clarify whether crocin affects LEDVT. Human umbilical vein endothelial cells (HUVECs) were exposed to thrombin and crocin (0, 5, 10, 20, 40, and 80 μM). Cell viability was assessed by MTT assay. Cellular behaviors were assessed using flow cytometry, TUNEL assay, and tube formation assay. The binding relationship between crocin and PIM1 was analyzed by molecular docking. The underlying mechanism of PIM1 was determined by reverse transcription-quantitative PCR, dual-luciferase reporter assay, and RIP. We found that crocin (5, 10, 20, and 40 μM) promoted thrombin-treated HUVEC viability in a dose-dependent manner. Crocin inhibited apoptosis and promoted the angiogenesis of HUVECs induced by thrombin. PIM1 was a target of crocin and was upregulated in patients with LEDVT and thrombin-treated cells. Foxo3a could interact with PIM1 and positively related to PIM1 expression. Moreover, the knockdown of PIM1 suppressed apoptosis and promoted angiogenesis in thrombin-HUVECs treated with crocin, while overexpression of Foxo3a reversed the effects. In conclusion, crocin inhibited apoptosis and promoted the angiogenesis of HUVECs induced by thrombin via the PIM1/Foxo3a axis, suggesting that crocin may be effective for LEDVT therapy.